exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274732 RNA Name: hsa-miR-330-5p RNA Type: miRNA Chromosome: chr19 Starnd: - Coordinate: Start Site(bp): 45639049 End Site(bp): 45639070 External Links: hsa-miR-330-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ZNF3 chr7 100064033 100082548 - ALDH5A1 chr6 24494867 24537207 + ENG chr9 127815012 127854756 - NEMP1 chr12 57055643 57088063 - STX3 chr11 59713456 59805882 + RTL10 chr22 19846138 19854896 - GIPC1 chr19 14477760 14496149 - ANKRD13B chr17 29589769 29614761 + UBE4A chr11 118359585 118399211 + MARK2 chr11 63838928 63911019 + ATXN1 chr6 16299112 16761491 - NME4 chr16 396725 410367 + TMEM127 chr2 96248516 96265994 - PDXK chr21 43719094 43762307 + GUCD1 chr22 24540423 24555935 - MTG2 chr20 62183029 62203568 + VLDLR chr9 2621787 2660056 + EIF4A1 chr17 7572706 7579006 + GIGYF1 chr7 100679507 100694037 - DOLPP1 chr9 129081111 129090438 + SMAD3 chr15 67063763 67195169 + MAP4 chr3 47850690 48089272 - ABL1 chr9 130713016 130887675 + PAQR4 chr16 2969270 2973484 + NR4A2 chr2 156324437 156342348 - CRTC3 chr15 90529923 90645345 + PPME1 chr11 74171267 74254703 + GOSR2 chr17 46923075 46975524 + MYO1C chr17 1464186 1492686 - AGTRAP chr1 11736084 11754802 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000128 chr1 151139409 151139890 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001727 chr7 99621041 99621930 + hsa_circ_0001865 chr9 86292641 86293514 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC144548.1 chr12 110387463 110445548 - AL355075.4 chr14 20343048 20343685 - AL359924.1 chr1 237862175 237928321 + AP000553.1 chr22 21652270 21670237 + KCNQ1OT1 chr11 2608328 2699994 - MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + SNHG1 chr11 62851984 62855953 - SNHG3 chr1 28505980 28510892 + TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.